Cogent Biosciences, Inc.
COGT
Rang in aandelen
#3253
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Aandeelprijs
$31.37
Laatst gesynchroniseerd: 2026-10-20
Marktkapitalisatie
$5.44B
Verandering (1 dag)
4.54%
Verandering (1 jaar)
97.81%
Land
US
Handel Cogent Biosciences, Inc. (COGT)
Categorie
Healthcare
P/B-ratio voor Cogent Biosciences, Inc. (COGT)
P/B-ratio op October 2026 TTM: 9.04
Volgens de meest recente financiële rapporten en aandelenkoers van Cogent Biosciences, Inc. is de huidige P/B-ratio (TTM) 9.04. Eind 2023 had het bedrijf een P/B-ratio van 1.82.
P/B-ratiohistoriek voor Cogent Biosciences, Inc. van 2015 tot 2026
P/B-ratio aan het einde van elk jaar
| Jaar | P/B-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 9.04 | 186.14% |
| 2024 | 3.16 | 73.98% |
| 2023 | 1.82 | -31.58% |
| 2022 | 2.66 | 71.14% |
| 2021 | 1.55 | 192.57% |
| 2020 | 0.53 | -23.25% |
| 2019 | 0.69 | -62.01% |
| 2018 | 1.82 | -84.34% |
| 2017 | 11.61 | 133.80% |
| 2016 | 4.97 | 32.70% |
| 2015 | 3.74 | 0.00% |
P/B-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/B-ratio | Verschil in P/B-ratio | Land |
|---|---|---|---|
| 6.251 | -30.87% |
US
|
|
| 13.2547 | 46.59% |
US
|
|
| 4.208 | -53.46% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -31.62% |
NL
|
